(Q33511367)

English

Early termination of ISRCTN45828668, a phase 1/2 prospective, randomized study of sulfasalazine for the treatment of progressing malignant gliomas in adults

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Early termination of ISRCTN45828668, a phase 1/2 prospective, randomized study of sulfasalazine for the treatment of progressing malignant gliomas in adults (English)

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

1 reference

based on heuristic

inferred from title

10

object named as

Vincent Bours

0 references

Sophie Vanbelle

object named as

Sophie Vanbelle

7

0 references

object named as

Didier H Martin

2

0 references

author name string

Pierre A Robe

1

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Minh T Nguyen-Khac

3

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Maria Artesi

4

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Manuel Deprez

5

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Adelin Albert

6

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Stephane Califice

8

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Markus Bredel

9

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

language of work or name

0 references

publication date

19 October 2009

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

9

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

372

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

copyright license

Creative Commons Attribution 2.0 Generic

19 October 2009

1 reference

April 2022 Public Data File from Crossref

copyright status

1 reference

April 2022 Public Data File from Crossref

https://scigraph.springernature.com/pub.10.1186/1471-2407-9-372

0 references

Validation of real-time methylation-specific PCR to determine O6-methylguanine-DNA methyltransferase gene promoter methylation in glioma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2771045

21 June 2018

Genomic changes and gene expression profiles reveal that established glioma cell lines are poorly representative of primary human gliomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2771045

21 June 2018

The x(c)- cystine/glutamate antiporter: a potential target for therapy of cancer and other diseases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2771045

21 June 2018

Expression of the constitutively activated RelA/NF-kappaB in human astrocytic tumors and the in vitro implication in the regulation of urokinase-type plasminogen activator, migration, and invasion

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2771045

21 June 2018

Sulfasalazine unveils a contact-independent HSV-TK/ganciclovir gene therapy bystander effect in malignant gliomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2771045

21 June 2018

Can NF-kappaB be a target for novel and efficient anti-cancer agents?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2771045

21 June 2018

A phase 1-2, prospective, double blind, randomized study of the safety and efficacy of Sulfasalazine for the treatment of progressing malignant gliomas: study protocol of [ISRCTN45828668].

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2771045

21 June 2018

Signaling mechanisms regulating endothelial permeability

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2771045

21 June 2018

Tumor necrosis factor-alpha-induced protein 3 as a putative regulator of nuclear factor-kappaB-mediated resistance to O6-alkylating agents in human glioblastomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2771045

21 June 2018

GNOSIS: guidelines for neuro-oncology: standards for investigational studies-reporting of phase 1 and phase 2 clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2771045

21 June 2018

Inhibition of cellular proliferation and induction of apoptosis by curcumin in human malignant astrocytoma cell lines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2771045

21 June 2018

Inhibition of cystine uptake disrupts the growth of primary brain tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2771045

21 June 2018

MGMT gene silencing and benefit from temozolomide in glioblastoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2771045

21 June 2018

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2771045

21 June 2018

In vitro and in vivo activity of the nuclear factor-kappaB inhibitor sulfasalazine in human glioblastomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2771045

21 June 2018

Aberrant nuclear factor-kappaB activity and its participation in the growth of human malignant astrocytoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2771045

21 June 2018

Nuclear factor-kappa B, cancer, and apoptosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2771045

21 June 2018

Decreased endothelial cell glutathione and increased sensitivity to oxidative stress in an in vitro blood-brain barrier model system.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2771045

21 June 2018

Alpha-melanocyte-stimulating hormone inhibits the nuclear transcription factor NF-kappa B activation induced by various inflammatory agents.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2771045

21 June 2018

The DNA-dependent protein kinase participates in the activation of NF kappa B following DNA damage

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2771045

21 June 2018

Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2771045

21 June 2018

Methotrexate and sulfasalazine promote adenosine release by a mechanism that requires ecto-5'-nucleotidase-mediated conversion of adenine nucleotides

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2771045

21 June 2018

Sulfasalazine-associated encephalopathy in a patient with Crohn's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2771045

21 June 2018

Sulfasalazine. A review of its pharmacological properties and therapeutic efficacy in the treatment of rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2771045

21 June 2018

Sulfasalazine aggravates experimental autoimmune encephalomyelitis and causes an increase in the number of autoreactive T cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2771045

21 June 2018

Adenosine and its nucleotides stimulate proliferation of chick astrocytes and human astrocytoma cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2771045

21 June 2018

Expression of nuclear factor-kappa B, tumor necrosis factor receptor type 1, and c-Myc in human astrocytomas.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-9-372

21 January 2018

Analysis of the activation status of Akt, NFkappaB, and Stat3 in human diffuse gliomas

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-9-372

21 January 2018

The ATM protein is required for sustained activation of NF-kappaB following DNA damage.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-9-372

21 January 2018

Response criteria for phase II studies of supratentorial malignant glioma

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-9-372

21 January 2018

Salazosulfapyridine-induced encephalopathy with symmetrical lesions in the basal ganglia and thalami.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-9-372

21 January 2018

Reversible encephalopathy due to sulfasalazine

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-9-372

21 January 2018

Drug induced intracranial hypertension associated with sulphasalazine treatment.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-9-372

21 January 2018

Identifiers

10.1186/1471-2407-9-372

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33511367&oldid=1981600405"